Effect of the emphysema subtypes of patients with chronic obstructive pulmonary disease on airway inflammation and COTE index

Liu,Zheng; Shi,Fang; Liu,Jun‑Xia; Gao,Chang‑Lan; Pei,Meng‑Miao; Li,Jing; Li,Pei‑Xiu

doi:10.3892/etm.2018.6799

Effect of the emphysema subtypes of patients with chronic obstructive pulmonary disease on airway inflammation and COTE index

Authors:
- Zheng Liu
- Fang Shi
- Jun‑Xia Liu
- Chang‑Lan Gao
- Meng‑Miao Pei
- Jing Li
- Pei‑Xiu Li
View Affiliations

Affiliations: Department of Respiratory Tract Medicine, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei 065000, P.R. China, Department of Radiology, The Petroleum Clinical Medical College of Hebei Medical University, Langfang, Hebei 065000, P.R. China
Published online on: September 27, 2018 https://doi.org/10.3892/etm.2018.6799
Pages: 4745-4752

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was investigate the association of the severity of emphysema of patients with chronic obstructive pulmonary disease (COPD) with airway inflammation and the COPD‑specific comorbidity test (COTE) index. A total of 94 patients with COPD were divided into four groups according to the severity of their emphysema; in each patient, comorbidities were recorded and inflammatory biomarkers, including MMP‑9 and TIMP‑1 were determined in circulating blood. The unbalanced proportion of MMP‑9 and its inhibitor, TIMP‑1, led to the airway inflammation and lung remodeling in the patients with COPD. A total of 80.85% of the patients had emphysema of different degrees. The quantity of male patients and the smoking index in the three emphysema groups were significantly higher than those in the non‑emphysema group (F=7.67 and 5.42, P<0.05). The level of the predicted percent offorced expiratory volume in 1 sec in the non‑emphysema group were significantly higher than those in the emphysema group (4.33; P<0.05), and the level of D‑dimer in the non‑emphysema group was significantly lower than that in the mild and moderate emphysema groups (F=9.38, P<0.05). The low‑attenuation area score was negatively correlated with inhaled bronchodilators (r=‑0.240, P=0.007) but positively correlated with the frequency of acute exacerbations in the previous year (r=0.211, P=0.001). In terms of treatment, the use of systemic hormone therapy in the emphysema group was more frequent than that in the non‑emphysema group (F=6.21, 12.92 and 4.08, P<0.05). The level of MMP‑9 was significantly higher in COPD patients with >3 comorbidities, a COTE index of ≥4 and cardiovascular disease as well as coronary heart disease (t=6.40, 2.53, 3.65 and 2.90, P<0.05). The level of MMP‑9 was positively correlated with the neutrophilic granulocyte percentage, the number of comorbidities and the COTE index (r=0.193, 0.402 and 0.311, P<0.01). The severity of emphysema in patients with COPD was correlated with the persistence of inflammatory factors in the circulating blood and the frequency of acute exacerbations. It was indicated that MMP‑9 has a critical role in numerous comorbidities of COPD.

View Figures

View References

1	Ostridge K, Williams N, Kim V, Harden S, Bourne S, Coombs NA, Elkington PT, Estepar RS, Washko G, Staples KJ and Wilkinson TM: Distinct emphysema subtypes defined by quantitative CT analysis are associated with specific pulmonary matrix metalloproteinases. Respir Res. 17:922016. View Article : Google Scholar : PubMed/NCBI
2	Papakonstantinou E, Karakiulakis G, Batzios S, Savic S, Roth M, Tamm M and Stolz D: Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection. Respir Res. 16:782015. View Article : Google Scholar : PubMed/NCBI
3	Smith BM, Austin JH, Newell JD Jr, D'Souza BM, Rozenshtein A, Hoffman EA, Ahmed F and Barr RG: Pulmonary emphysema subtypes on computed tomography: The MESA COPD study. Am J Med. 127:94.e7–e23. 2014. View Article : Google Scholar
4	Foster WL Jr, Pratt PC, Roggli VL, Godwin JD, Halvorsen RA Jr and Putman CE: Centrilobular emphysema: CT-pathologic correlation. Radiology. 159:27–32. 1986. View Article : Google Scholar : PubMed/NCBI
5	Hruban RH, Meziane MA, Zerhouni EA, Khouri NF, Fishman EK, Wheeler PS, Dumler JS and Hutchins GM: High resolution computed tomography of inflation-fixed lungs. Pathologic-radiologic correlation of centrilobular emphysema. Am Rev Respir Dis. 136:935–940. 1987. View Article : Google Scholar : PubMed/NCBI
6	Montaño M, Sansores RH, Becerril C, Cisneros J, González-Avila G, Sommer B, Ochoa L, Herrera I, Ramírez-Venegas A and Ramos C: FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. Respir Res. 15:742014.PubMed/NCBI
7	Grzela K, Litwiniuk M, Zagorska W and Grzela T: Airway remodeling in chronic obstructive pulmonary disease and asthma: The role of matrix metalloproteinase-9. Arch Immunol Ther Exp (Warsz). 64:47–55. 2016. View Article : Google Scholar : PubMed/NCBI
8	Jia TG, Zhao JQ and Liu JH: Serum inflammatory factor and cytokines in AECOPD. Asian Pac J Trop Med. 7:1005–1008. 2014. View Article : Google Scholar : PubMed/NCBI
9	Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al: Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 186:155–161. 2002. View Article : Google Scholar
10	Celli BR and MacNee W; ATS/ERS Task Force, : Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 23:932–946. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kitaguchi Y, Fujimoto K, Kubo K and Honda T: Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med. 100:1742–1752. 2006. View Article : Google Scholar : PubMed/NCBI
12	Roberts HR, Wells AU, Milne DG, Rubens MB, Kolbe J, Cole PJ and Hansell DM: Airflow obstruction in bronchiectasis: Correlation between computed tomography features and pulmonary function tests. Thorax. 55:198–204. 2000. View Article : Google Scholar : PubMed/NCBI
13	The definition of emphysema. Report of a National Heart, Lung, and Blood Institute, Division of Lung Diseases workshop. Am Rev Respir Dis. 132:182–185. 1985.PubMed/NCBI
14	Hoffman EA, Simon BA and Mclennan G: State of the art. A structural and functional assessment of the lung via multidetector-row computed tomography: Phenotyping chronic obstructive pulmonary disease. Proc Am Thorac Soc. 3:519–532. 2006. View Article : Google Scholar : PubMed/NCBI
15	Singh S, Loke YK, Enright PL and Furberg CD: Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis of randomised controlled trials. BMJ. 342:d32152011. View Article : Google Scholar : PubMed/NCBI
16	Dar KA, Shahid M, Mubeen A, Bhargava R, Ahmad Z, Ahmad I and Islam N: The role of noninvasive methods in assessing airway inflammation and structural changes in asthma and COPD. Monaldi Arch Chest Dis. 77:8–18. 2012.PubMed/NCBI
17	Kwiatkowska S, Noweta K, Zieba M, Nowak D and Bialasiewicz P: Enhanced exhalation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with COPD exacerbation: A prospective study. Respiration. 84:231–241. 2012. View Article : Google Scholar : PubMed/NCBI
18	Linder R, Rönmark E, Pourazar J, Behndig A, Blomberg A and Lindberg A: Serum metallopteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population based cohort-study. Respir Res. 16:282015. View Article : Google Scholar : PubMed/NCBI
19	Anderson AE Jr and Foraker AG: Centrerilobolar emphysema and panlobular emphysema: Two different diseases. Thorax. 28:547–550. 1973. View Article : Google Scholar : PubMed/NCBI
20	Saetta M, Kim WD, Izquierdo JL, Ghezzo H and Cosio MG: Extent of centriobular and panacinar emphysema in smokers'lungs: Pathological and mechanical implications. Eur Respir J. 7:664–671. 1994. View Article : Google Scholar : PubMed/NCBI
21	Kawayama T, Kinoshita T, Matsunaga K, Kobayashi A, Hayamizu T, Johnson M and Hoshino T: Responsiveness of blood and sputum inflammatory cells in Japanese copd patients, non-copd smoking controls, and non-copd nonsmoking controls. Int J Chron Obstruct Pulmon Dis. 11:295–303. 2016.PubMed/NCBI
22	Segura-Valdezl L, Pardo A, Gaxiola M, Uhal BD, Becerril C and Selman M: Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest. 117:684–694. 2000. View Article : Google Scholar : PubMed/NCBI
23	Linder R, Rönmark E, Pourazar J, Behndig A, Blomberg A and Lindberg A: Serum metalloproteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population based cohort-study. Respir Res. 16:282015. View Article : Google Scholar : PubMed/NCBI
24	Hong Y, Ji W, An S, Han SS, Lee SJ and Kim WJ: Sex differences of COPD phenotypes in nonsmoking patiens. Int J Chron Obstruct Pulmon Dis. 11:1657–1662. 2016. View Article : Google Scholar : PubMed/NCBI
25	Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK and Criner GJ; COPDGene Investigators, : The chronic bronchitic phenotype of COPD: An analysis of the COPDGene study. Chest. 140:626–633. 2011. View Article : Google Scholar : PubMed/NCBI
26	Smith MC and Wrobel JP: Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 9:871–888. 2014. View Article : Google Scholar : PubMed/NCBI
27	Selvarajah S, Todd I, Tighe PJ, John M, Bolton CE, Harrison T and Fairclough LC: Multiple Circulating cytokines are coelevated in chronic obstrictive pulmonary disease. Mediators Inflamm. 2016:36048422016. View Article : Google Scholar : PubMed/NCBI
28	Eickhoff P, Valipour A, Kiss D, Schreder M, Cekici L, Geyer K, Kohansal R and Burghuber OC: Determinants of systemic vascular function in patients wity stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 178:1211–1218. 2008. View Article : Google Scholar : PubMed/NCBI
29	Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, Regan E, Bailey WC, Martinez FJ, Westfall E, et al: Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl Med. 367:913–921. 2012. View Article : Google Scholar